Next-generation sequencing (NGS) can help pharmaceutical and biotech researchers better understand the genetic variants associated with various diseases. These insights can support the development of targeted therapeutics and multi-analyte tumor analysis. NGS also opens the door for discovery of novel methods to monitor cancer treatment and recurrence.
lllumina brings innovation to drug development by offering comprehensive genomic solutions working in collaboration with leading pharmaceutical providers.
As targeted therapies make their way through pharmaceutical pipelines, the need for companion diagnostics is increasing.Learn More
NGS helps drug developers to explore genomic variation. This informs target discovery, validation, and clinical development.Learn More
A groundbreaking international clinical study has succeeded in integrating imaging, multiomic technologies, and data analysis into a powerful drug discovery engine. The Global Genomics Group (G3) has demonstrated the value of its novel approach, with the introduction of a new diagnostic and several drug candidates in development with pharmaceutical partners.Read Article